Ibogaine research faces representation challenges

Ibogaine research is under scrutiny for its lack of representation of marginalized groups in clinical trials, according to a report by TalkingDrugs. This issue was a focal point at the International Conference of Psychedelic Research (ICPR 2026), where experts discussed the structural biases inherent in the current medical model of psychedelic research.

Structural biases in psychedelic research

The report highlights that the exclusion of women, minorities, and gender-diverse individuals from clinical trials is not merely a data collection oversight but a structural issue within the Western biomedical model. This model assumes conditions such as safety and institutional trust, which are not universally available. Participants in trials are often asked to engage with institutions that may have historically marginalized their communities, posing significant barriers to participation.

Ibogaine and addiction treatment

Ibogaine, a psychoactive substance under investigation for addiction treatment, exemplifies the gap between research promise and reality. While ibogaine shows potential, those most likely to benefit—such as individuals experiencing homelessness or those in contact with the carceral system—are often absent from trials. These groups face challenges in accessing clinical care, highlighting the limitations of the current research framework.

The colonial critique

The use of ibogaine also raises concerns about cultural appropriation. The plant iboga, from which ibogaine is derived, has been used in African cultural contexts for centuries. Critics argue that Western clinical frameworks inadequately address the cultural depth of such substances, with panelist Ronica Mukerjee describing this as an "arrogance of western medical practitioners."

Community-based alternatives

The conference proposed community-based models as alternatives to the medicalized approach. These models emphasize trust and cultural knowledge, elements often missing in clinical settings. Practitioners like Rafaelle Lancelotta advocate for harm reduction and integration support outside formal clinical models, highlighting the need for community involvement in psychedelic therapy.

Why it matters

The representation crisis in ibogaine research underscores a broader issue in psychedelic medicine: the need to include diverse populations in research and treatment frameworks. Without addressing these gaps, the field risks perpetuating inequities and failing to serve those who could benefit most from psychedelic therapies.

The ongoing dialogue at ICPR 2026 suggests a growing awareness of these issues, but significant work remains to ensure that psychedelic research and treatment are truly inclusive and equitable.